BibTex RIS Cite

Doksorubisin ile Oluşturulmuş Deneysel Kardiyotoksisite Üzerine Nikotinamidin Etkisi

Year 2008, Volume: 39 Issue: 1, 7 - 14, 20.07.2014

Şule Ayla Hüseyin Oktar Gamze Tanrıverdi Müjgan Cengiz Anıl Özkılıç Nazan Böttjer Tuncay Altuğ Şebnem Batur

Keywords

Antineoplastik ajan doksorubisin nikotinamid deneysel kardiyotoksisite antioksidan

References

  • Saad SY, Najjar TA, Al-Rikabi AC. The preventive role deferoxamine against acute doxorubicin-induced cardiac, renal and hepatic toxicity in rats. Pharmacol Res 2001; 43: 211-218.
  • Akkufl ‹. Serbest Radikaller ve fizyopatolojik etkileri. Konya: Mimoza Yay›nlar›; 1995.
  • Kavas (Özelçi) G. Serbest radikaller ve organizma üzerine etkileri. Türkiye Klinikleri 1989; 9: 1-8.
  • Meram ‹., Aktaran fi. Serbest radikallerin biyomoleküller üzerine etkileri. Arfliv 2002; 1: 299-304.
  • Ya¤murca A, Bas O, Mollaoglu H, et al. Protective effects of erdosteine on doxorubicin-induced hepatotoxicity in rats. Arch Med Res 2007; 38: 380-385.
  • Wojtacki J, Lewicka-Nowak E, Lesniewski-Kmak K. Anthracycline-induced cardiotoxicity: clinical course, risk factors, pathogenesis, detection and prevention review of the literature. Med Sci Monit 2000; 6: 411412.
  • Tanr›verdi G. Karbon tetraklorür (CCL4) ile oluflturulmufl karaci¤er hasar›nda de¤iflik dozlardaki nikotinamidin protektif etkisinin ›fl›k ve elektron mikroskobik olarak incelenmesi [Yüksek Lisans Tezi]. ‹stanbul: ‹.Ü.Cerrahpafla T›p Fakültesi Histoloji ve Embriyoloji A.D.; 2005.
  • Cuzzocrea S, Riley DP, Caputi AP, Salvemini D, et al. Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. Pharmacol Rev 2001; 53: 135-159.
  • Damc› T. Koruyucu giriflimler. Diabetes Mellitus Sempozyumu. ‹stanbul; 151-156.
  • Beutler E, Blurne KG, Kaplan JC, et al. International Comitte for Standardization in Haematology: Recommended methods for red blood cell enzyme analysis. Br J Haematol 1977; 35: 331-340.
  • Habig WH, Pabst MJ, Jacob WB. Glutathione-S-transferase. The first enzymatic step in mercapturic acid formation. J Biol Chem 1974; 249: 7130-7139.
  • Aebi H. Catalase. In: Bergmeyer H.U, ed. Metods of enzymatic analysis. Newyork: Academic Press; 1974; 673-677.
  • Levine RL, Garland D, Oliver CV, et al. Determination of carbonyl content in oxidatively modified proteins. Meth Enzymol 1990; 186: 464-473.
  • Kayaalp O. Rasyonel tedavi yönünden t›bbi farmakoloji. Ankara: Günefl Bas›mevi; 2000; 1011-1013.
  • Singal PK, Iliskovic N, Kumar D. Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J 1997; 11: 931-936.
  • el-Shazly MO, Afify MM, el-Dieb MK. Histopathological study into side-effect toxicity of some drugs used in treatment of cancer. Arch Exp Veterinarmed 1989; 43: 319-326.
  • Fadillioglu E, Oztas E, Erdo¤an H, et al. protective effects of caffeic acid phenethyl ester on doxorubicininduced cardiotoxicity in rats. J Appl Toxicol 2004; 24: 47-52
  • Sacco G, Bigio M, Evangelista S, et al. Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat. Eur J Pharmacol 2001; 414: 71-78.
  • Venditti P, Balestrieri M, De Leo T, Di Meo S. Free radical involvement in doxorubucin-induced electrophysiological alterations in rat papillary muscle fibres. Cardiovasc Res 1998; 38: 695-702.
  • Siveski-‹liskovic N, Kaul N, Signal PK. Probucol prometes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats. Circulation 1994; 89: 2829-2835.
  • Sadzuka Y, Sugiyama T, Shimoi K, et al. Protective effect of flavonoids on doxorubicin-induced cardiotoxicity. Toxicol Lett 1997; 92: 1-7.
  • Myers C. The role of iron in doxorubicin-induced cardiomyopathy. Semin Oncol 1998; 25: 10-14.
  • Malarkodi PK, Balachandar AV, Varalakshmi P. Protective effect of lipoic acid on adriamycin induced lipid peroxidation in rat kidney. Mol Cell Biochem 2003; 247: 9-13.
  • Tesoriene L, Ciaccio M, Valenza M, et al. Effect of vitamin A administration on resistance of rat heart against doxorubicin-induced cardiotoxicity and lethality. J Pharm Exp Ther 1994; 269: 430-6.
  • Van Vlett JF, Ferrans VJ, Weirich WE. Cardiac disease induced by chronic adriamycin administration in dogs and an evaluation of vitamin E and selenium as cardioprotectants. Am J Pathol 1980; 99: 13-42.
  • Balli E, Mete ÖU, Tuli A, et al. Effect of melatonin on the cardiotoxicity of doxorubicin. Histol Histopatol 2004; 19: 1101-1108.
  • Ungersted JS, Blömback M, Söderström T. Nicotinamide is a potent inhibitor of proinflammatory cytokines. Clin Exp Immunol 2003; 131: 48-52.
  • Fukuzawa M, Satoh J, Muto G, et al. ‹nhibitory effect of nicotinamide on in vitro and in vivo production of tumor necrosis factor-alpha. Immunol Lett 1997; 59: 7-11.

Year 2008, Volume: 39 Issue: 1, 7 - 14, 20.07.2014

Şule Ayla Hüseyin Oktar Gamze Tanrıverdi Müjgan Cengiz Anıl Özkılıç Nazan Böttjer Tuncay Altuğ Şebnem Batur

References

  • Saad SY, Najjar TA, Al-Rikabi AC. The preventive role deferoxamine against acute doxorubicin-induced cardiac, renal and hepatic toxicity in rats. Pharmacol Res 2001; 43: 211-218.
  • Akkufl ‹. Serbest Radikaller ve fizyopatolojik etkileri. Konya: Mimoza Yay›nlar›; 1995.
  • Kavas (Özelçi) G. Serbest radikaller ve organizma üzerine etkileri. Türkiye Klinikleri 1989; 9: 1-8.
  • Meram ‹., Aktaran fi. Serbest radikallerin biyomoleküller üzerine etkileri. Arfliv 2002; 1: 299-304.
  • Ya¤murca A, Bas O, Mollaoglu H, et al. Protective effects of erdosteine on doxorubicin-induced hepatotoxicity in rats. Arch Med Res 2007; 38: 380-385.
  • Wojtacki J, Lewicka-Nowak E, Lesniewski-Kmak K. Anthracycline-induced cardiotoxicity: clinical course, risk factors, pathogenesis, detection and prevention review of the literature. Med Sci Monit 2000; 6: 411412.
  • Tanr›verdi G. Karbon tetraklorür (CCL4) ile oluflturulmufl karaci¤er hasar›nda de¤iflik dozlardaki nikotinamidin protektif etkisinin ›fl›k ve elektron mikroskobik olarak incelenmesi [Yüksek Lisans Tezi]. ‹stanbul: ‹.Ü.Cerrahpafla T›p Fakültesi Histoloji ve Embriyoloji A.D.; 2005.
  • Cuzzocrea S, Riley DP, Caputi AP, Salvemini D, et al. Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. Pharmacol Rev 2001; 53: 135-159.
  • Damc› T. Koruyucu giriflimler. Diabetes Mellitus Sempozyumu. ‹stanbul; 151-156.
  • Beutler E, Blurne KG, Kaplan JC, et al. International Comitte for Standardization in Haematology: Recommended methods for red blood cell enzyme analysis. Br J Haematol 1977; 35: 331-340.
  • Habig WH, Pabst MJ, Jacob WB. Glutathione-S-transferase. The first enzymatic step in mercapturic acid formation. J Biol Chem 1974; 249: 7130-7139.
  • Aebi H. Catalase. In: Bergmeyer H.U, ed. Metods of enzymatic analysis. Newyork: Academic Press; 1974; 673-677.
  • Levine RL, Garland D, Oliver CV, et al. Determination of carbonyl content in oxidatively modified proteins. Meth Enzymol 1990; 186: 464-473.
  • Kayaalp O. Rasyonel tedavi yönünden t›bbi farmakoloji. Ankara: Günefl Bas›mevi; 2000; 1011-1013.
  • Singal PK, Iliskovic N, Kumar D. Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J 1997; 11: 931-936.
  • el-Shazly MO, Afify MM, el-Dieb MK. Histopathological study into side-effect toxicity of some drugs used in treatment of cancer. Arch Exp Veterinarmed 1989; 43: 319-326.
  • Fadillioglu E, Oztas E, Erdo¤an H, et al. protective effects of caffeic acid phenethyl ester on doxorubicininduced cardiotoxicity in rats. J Appl Toxicol 2004; 24: 47-52
  • Sacco G, Bigio M, Evangelista S, et al. Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat. Eur J Pharmacol 2001; 414: 71-78.
  • Venditti P, Balestrieri M, De Leo T, Di Meo S. Free radical involvement in doxorubucin-induced electrophysiological alterations in rat papillary muscle fibres. Cardiovasc Res 1998; 38: 695-702.
  • Siveski-‹liskovic N, Kaul N, Signal PK. Probucol prometes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats. Circulation 1994; 89: 2829-2835.
  • Sadzuka Y, Sugiyama T, Shimoi K, et al. Protective effect of flavonoids on doxorubicin-induced cardiotoxicity. Toxicol Lett 1997; 92: 1-7.
  • Myers C. The role of iron in doxorubicin-induced cardiomyopathy. Semin Oncol 1998; 25: 10-14.
  • Malarkodi PK, Balachandar AV, Varalakshmi P. Protective effect of lipoic acid on adriamycin induced lipid peroxidation in rat kidney. Mol Cell Biochem 2003; 247: 9-13.
  • Tesoriene L, Ciaccio M, Valenza M, et al. Effect of vitamin A administration on resistance of rat heart against doxorubicin-induced cardiotoxicity and lethality. J Pharm Exp Ther 1994; 269: 430-6.
  • Van Vlett JF, Ferrans VJ, Weirich WE. Cardiac disease induced by chronic adriamycin administration in dogs and an evaluation of vitamin E and selenium as cardioprotectants. Am J Pathol 1980; 99: 13-42.
  • Balli E, Mete ÖU, Tuli A, et al. Effect of melatonin on the cardiotoxicity of doxorubicin. Histol Histopatol 2004; 19: 1101-1108.
  • Ungersted JS, Blömback M, Söderström T. Nicotinamide is a potent inhibitor of proinflammatory cytokines. Clin Exp Immunol 2003; 131: 48-52.
  • Fukuzawa M, Satoh J, Muto G, et al. ‹nhibitory effect of nicotinamide on in vitro and in vivo production of tumor necrosis factor-alpha. Immunol Lett 1997; 59: 7-11.
There are 28 citations in total.

Details

Primary Language English
Journal Section Araştırmalar
Authors

Şule Ayla This is me

Hüseyin Oktar This is me

Gamze Tanrıverdi This is me

Müjgan Cengiz This is me

Anıl Özkılıç This is me

Nazan Böttjer This is me

Tuncay Altuğ This is me

Şebnem Batur This is me

Publication Date July 20, 2014
Published in Issue Year 2008 Volume: 39 Issue: 1

Cite

APA Ayla, Ş., Oktar, H., Tanrıverdi, G., Cengiz, M., et al. (2014). Doksorubisin ile Oluşturulmuş Deneysel Kardiyotoksisite Üzerine Nikotinamidin Etkisi. Cerrahpaşa Tıp Dergisi, 39(1), 7-14.
AMA Ayla Ş, Oktar H, Tanrıverdi G, Cengiz M, Özkılıç A, Böttjer N, Altuğ T, Batur Ş. Doksorubisin ile Oluşturulmuş Deneysel Kardiyotoksisite Üzerine Nikotinamidin Etkisi. Cerrahpaşa Tıp Dergisi. July 2014;39(1):7-14.
Chicago Ayla, Şule, Hüseyin Oktar, Gamze Tanrıverdi, Müjgan Cengiz, Anıl Özkılıç, Nazan Böttjer, Tuncay Altuğ, and Şebnem Batur. “Doksorubisin Ile Oluşturulmuş Deneysel Kardiyotoksisite Üzerine Nikotinamidin Etkisi”. Cerrahpaşa Tıp Dergisi 39, no. 1 (July 2014): 7-14.
EndNote Ayla Ş, Oktar H, Tanrıverdi G, Cengiz M, Özkılıç A, Böttjer N, Altuğ T, Batur Ş (July 1, 2014) Doksorubisin ile Oluşturulmuş Deneysel Kardiyotoksisite Üzerine Nikotinamidin Etkisi. Cerrahpaşa Tıp Dergisi 39 1 7–14.
IEEE Ş. Ayla, “Doksorubisin ile Oluşturulmuş Deneysel Kardiyotoksisite Üzerine Nikotinamidin Etkisi”, Cerrahpaşa Tıp Dergisi, vol. 39, no. 1, pp. 7–14, 2014.
ISNAD Ayla, Şule et al. “Doksorubisin Ile Oluşturulmuş Deneysel Kardiyotoksisite Üzerine Nikotinamidin Etkisi”. Cerrahpaşa Tıp Dergisi 39/1 (July 2014), 7-14.
JAMA Ayla Ş, Oktar H, Tanrıverdi G, Cengiz M, Özkılıç A, Böttjer N, Altuğ T, Batur Ş. Doksorubisin ile Oluşturulmuş Deneysel Kardiyotoksisite Üzerine Nikotinamidin Etkisi. Cerrahpaşa Tıp Dergisi. 2014;39:7–14.
MLA Ayla, Şule et al. “Doksorubisin Ile Oluşturulmuş Deneysel Kardiyotoksisite Üzerine Nikotinamidin Etkisi”. Cerrahpaşa Tıp Dergisi, vol. 39, no. 1, 2014, pp. 7-14.
Vancouver Ayla Ş, Oktar H, Tanrıverdi G, Cengiz M, Özkılıç A, Böttjer N, Altuğ T, Batur Ş. Doksorubisin ile Oluşturulmuş Deneysel Kardiyotoksisite Üzerine Nikotinamidin Etkisi. Cerrahpaşa Tıp Dergisi. 2014;39(1):7-14.